InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,277.29
(
0.30%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 60
Posts 11512
Boards Moderated 0
Alias Born 07/16/2006

jbog

Member Level

Re: DewDiligence post# 82943

Friday, 08/28/2009 6:55:13 AM

Friday, August 28, 2009 6:55:13 AM

Post# of 252302
Dew, Regarding the NSCLC Biomarker

I noticed that Pfizer has a presentation detailing an phase I trial using PF- 02341066 [oral c-met and ALK inhibitor] at ESMO next month. It's being presented in the "Presidential, Best Of 2009" group. Bipar's BSI-201 [PARP1] inhibitor is in the same group.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up